Taker Shipping Improved Breast Cancer Drugs to Patients in China
Tower Pharmaceuticals Holdings Inc. a leader in developing novel AIDS therapeutics joining the broad cancer research community today announced the publication of a peer-reviewed editorial in The Journal of Nuclear Medicine in which eight leading scientists including multiple representatives from the U. S. and Canada discuss how the companys novel drug candidate improved the survival of two HIV positive Hepatoma patients. The innovative treatment was developed in collaboration with the Broad Institute in the form of a single-target controlled-dose regimen.
Tower Vice President and Scientific Director Eliot U. Gordon MD MBA president and CEO of the Institute of Hematology Oncology and Oncology at The University of Texas Medical Branch at Austin wrote:We are thankful to have been part of this landmark article and continue to support the revolutionary work of Dr. Gordon.
In its most recent annual report the Institute of Hematology Oncology and Oncology at The University of Texas Medical Branch found that over the next 6 years the Institute of Hematology Oncology and Oncology including the Broad Institute proactively offered RESHOLEN to more than 3600 patients in 30 countries on a commercial scale. This is the first time the Foundation of American researchers has offered a state-of-the-art broadly-diverse therapy approach between the patientprimary care and health center level for cancer.
The program was developed with the stakeholder health care community in that the platform was developed with input from its partners in Washington California and Texas across multiple medical centers tertiary health care sites and research institutions. The platform was also adaptable to the unique needs of cancer patients which essentially meant that the therapy tailored to specific patient needs could be tested and optimized against each individual patients cancer.
This novel therapy would be a promising treatment option for patients with present or recurrent aggressive cancers including glioblastoma a brain tumor with a poor prognosis. The paper also describes the preclinical animal models tested in this treatment and the potential prophylactic approaches for use in clinical patients with glioblastomas a common brain tumor with a poor prognosis.
The paper also discusses how the new drug candidate can offer the benefit of patients much more quickly than other known treatments in effect for acute treatment.